Novo Nordisk (NVO.N): Semaglutide can reduce the risk of myocardial infarction and stroke by 25%, and is associated with a 25% reduction in the overall risk of major adverse cardiovascular events such as myocardial infarction, stroke, hospitalization for unstable angina or heart failure, and death.

2025-09-18 16:49:27

Novo Nordisk

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Musk: XAI will certainly raise funds in the next few months, but not now
                            2025-09-20

                                    Nvidia (NVDA.O) fell further, dropping nearly 3%.
                            2025-09-17

                                    SoftBank and OpenAI's AI joint venture in Japan is severely delayed, with an update now expected in November.
                            2025-09-18

                                    HGTECH's 3.2T NPO products are used by leading industry customers
                            2025-09-24

                                    Alipay's two operating entities have completed the name change
                            2025-09-19